Description
RAZINA-500 SR Tablet contains Ranolazine 500 mg in a sustained-release formulation, an antianginal medicine used to help manage chronic angina (chest discomfort caused by reduced blood flow to the heart). Ranolazine belongs to the antianginal class and may be prescribed as part of a comprehensive treatment plan when additional symptom control is required.
The sustained-release formulation is designed to release the active ingredient gradually. Ranolazine helps reduce the frequency of chronic angina symptoms in appropriate patients. It is not intended to treat a sudden angina attack or replace emergency treatment for new, severe or worsening chest pain. Its use should be guided by a qualified healthcare professional.
CardianCare provides a contact point for pharmaceutical product and trade enquiries. Businesses searching for a Ranolazine 500 mg sustained-release Tablets manufacturer India can enquire about product availability, approved specifications, manufacturing-source details and applicable quality documentation.
For procurement teams evaluating a Ranolazine 500 mg sustained-release Tablets manufacturer and supplier India, important considerations include composition accuracy, release characteristics, product authorization, packaging, batch traceability, shelf life and storage requirements.
2. Key Ingredient
Composition: Ranolazine 500 mg Sustained Release
Ranolazine is an antianginal medicine used to help manage chronic angina. It works through effects on cardiac ion-channel activity, particularly by inhibiting the late inward sodium current in heart muscle cells. This can help reduce abnormal sodium and calcium accumulation within these cells and improve myocardial relaxation.
The sustained-release formulation is designed to release ranolazine over an extended period. The Tablet must be taken according to the approved product instructions, and the release characteristics should be confirmed against the product’s authorized labelling.
Businesses researching a Ranolazine 500 mg sustained-release pharmaceutical company India should assess the approved formulation, release mechanism, product authorization, labelling and applicable quality documentation.
Companies evaluating a Ranolazine 500 mg sustained-release medicine manufacturer India should verify the legal manufacturing source, regulatory status, batch documentation and formulation-specific quality requirements before procurement.
3. Key Benefits
Chronic angina management: Helps reduce chronic angina symptoms in appropriately selected patients.
Antianginal action: Provides a treatment option that works through a mechanism different from many conventional antianginal medicines.
Sustained-release formulation: Designed to release the active ingredient gradually according to the approved formulation.
Potential add-on therapy: May be prescribed alongside other angina medicines when clinically appropriate.
Symptom-management support: May help improve the ability to carry out daily activities when angina symptoms are better controlled.
Clinician-guided treatment: Can be incorporated into an individualized cardiovascular care plan with appropriate monitoring.
Treatment response varies between patients. Ranolazine does not replace lifestyle measures, risk-factor management or other cardiovascular treatments recommended by the treating clinician.
Pharmaceutical buyers searching for a Ranolazine 500 mg sustained-release supplier India should verify product authenticity, current availability, approved specifications, shelf life and supporting documentation.
A Ranolazine 500 mg sustained-release Tablet wholesaler and distributor India enquiry may cover stock availability, minimum order quantities, delivery coverage, licensing requirements and applicable commercial terms.
Businesses seeking a Ranolazine 500 mg sustained-release bulk supplier India should request a formal quotation and confirm packaging specifications, storage conditions, batch traceability and quality documentation.
A Ranolazine 500 mg sustained-release pharmaceutical distributor India should verify distribution eligibility, product authorization and approved promotional information before beginning commercial activities.
4. How Does It Work?
Ranolazine inhibits the late inward sodium current in cardiac cells. Excessive late sodium entry can contribute to increased intracellular sodium and calcium levels, which may impair the relaxation of heart muscle.
By reducing this current, ranolazine may improve myocardial relaxation and reduce the adverse effects associated with increased cellular calcium. Its antianginal effect does not depend primarily on lowering heart rate or blood pressure, although individual responses and concomitant treatments must still be considered.
Ranolazine may affect the QT interval on an electrocardiogram. Healthcare professionals should assess the patient’s medical history, interacting medicines and other risk factors before prescribing it.
5. Directions for Use
Dosage: Take only as prescribed by a doctor. The appropriate dose and frequency depend on the approved product information, clinical response and individual risk factors.
Administration: Follow the approved pack instructions. Sustained-release Tablets are generally swallowed whole with water; do not crush, chew or break them unless the product’s approved instructions specifically permit this.
Consistent timing: Take the medicine according to the prescribed schedule and avoid changing the dose independently.
Missed dose: Follow the patient leaflet or advice from a healthcare professional. Do not take extra Tablets to compensate for a missed dose.
Treatment monitoring: Inform the doctor about persistent symptoms, new adverse effects or any change in cardiovascular health.
Angina emergency: This medicine is not intended for immediate relief of an acute angina attack. Follow the emergency action plan provided by the treating clinician for sudden or severe chest pain.
The prescribed regimen should be based on the approved product information and the patient’s individual clinical circumstances.
6. Possible Side Effects
Possible side effects of ranolazine include:
Dizziness
Headache
Constipation
Nausea
Weakness or fatigue
Important safety concerns
QT prolongation: Ranolazine can prolong the QT interval, potentially increasing the risk of serious abnormal heart rhythms in susceptible patients.
Palpitations or fainting: New palpitations, fainting or near-fainting require prompt medical assessment.
Low blood pressure or dizziness: Dizziness may increase the risk of falls, particularly when starting treatment or taking interacting medicines.
Allergic reactions: Swelling, rash or difficulty breathing requires urgent medical attention.
This list is not exhaustive. Patients should report persistent or concerning symptoms to a healthcare professional.
7. Safety Information
Medical supervision: Use only under the guidance of a qualified healthcare professional.
Contraindications: Follow the approved product information. Ranolazine should not be used in patients with known serious hypersensitivity to the medicine or where the approved label lists a contraindication.
Heart rhythm: Tell the prescriber about a history of prolonged QT interval, abnormal heart rhythms, fainting or a family history of serious rhythm disorders.
Liver health: Significant liver impairment may increase risk and can be a contraindication. Inform the prescriber about any liver disease.
Kidney health: Kidney impairment may require additional assessment and monitoring. Follow the approved product instructions and the clinician’s advice.
Drug interactions: Ranolazine has clinically important interactions with medicines that affect CYP3A enzymes and with other QT-prolonging drugs. Tell the doctor about all prescription medicines, over-the-counter products and supplements.
Pregnancy and breastfeeding: Consult a healthcare professional before use during pregnancy, when planning pregnancy or while breastfeeding. The clinician should assess potential benefits and risks.
Driving and machinery: Dizziness or blurred vision may affect the ability to drive or operate machinery. Avoid these activities if affected.
Storage: Keep the medicine in its original packaging and follow the approved label’s storage instructions. Protect it from excessive heat and moisture as directed, and keep it out of children’s reach.
This information is educational and does not replace approved prescribing information or individualized medical advice.
8. B2B Pharmaceutical Business Enquiries
CardianCare provides a contact point for pharmaceutical product and trade enquiries. Doctors, pharmacists, procurement teams, wholesalers, distributors and eligible pharmaceutical business partners can contact the company to ask about current product availability and applicable commercial arrangements.
Businesses researching a Ranolazine 500 mg sustained-release PCD pharma franchise India opportunity should confirm directly whether the product and a relevant programme are available, including territory eligibility, partner requirements and commercial terms.
For a Ranolazine 500 mg sustained-release Tablets PCD pharma franchise enquiry, prospective partners can request information about product availability, minimum order quantities, licensing requirements, distribution eligibility and any applicable promotional support.
Companies exploring a Ranolazine 500 mg sustained-release Tablet PCD franchise should verify programme availability and product eligibility before making investment or promotional commitments.
Businesses evaluating Ranolazine 500 mg sustained-release third party manufacturing India services should first confirm whether the proposed company offers such arrangements. Due diligence should include manufacturing authorization, applicable GMP compliance, product approvals, sustained-release formulation controls and quality documentation.
A Ranolazine 500 mg sustained-release Tablet third party manufacturer India enquiry should cover the manufacturing facility’s regulatory status, formulation validation, quality systems, batch-release procedures, packaging specifications and contractual responsibilities.
Companies investigating Ranolazine 500 mg sustained-release contract manufacturing India should confirm service availability and discuss formulation specifications, release-profile requirements, technical documentation, quality agreements, regulatory responsibilities and commercial feasibility with the proposed manufacturing partner.
Contact CardianCare through its official website to enquire about current product availability, pharmaceutical distribution opportunities and applicable business arrangements. PCD franchise, third-party manufacturing and contract manufacturing services must be confirmed directly before being represented as available.
9. For More Information – Ranolazine 500 mg
For more information about RAZINA-500 SR Tablet (Ranolazine 500 mg Sustained Release), click here













Reviews
There are no reviews yet.